Marinus Historical Balance Sheet

MRNS Stock

USD 1.29 0.04 3.01%

Trend analysis of Marinus Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 42.7 M provides information on Marinus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Marinus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Marinus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Marinus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Marinus Pharmaceuticals is a good buy for the upcoming year.

Marinus Pharmaceuticals Inventory

2.53 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.

About Marinus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Marinus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Marinus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Marinus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Marinus currently owns. An asset can also be divided into two categories, current and non-current.

Marinus Pharmaceuticals Balance Sheet Chart

Marinus Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Marinus Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Marinus Pharmaceuticals' Total Liabilities is comparatively stable compared to the past year. Property Plant And Equipment Gross is likely to gain to about 6 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 15.9 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Marinus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Marinus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Marinus Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Marinus Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Marinus Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Marinus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.At this time, Marinus Pharmaceuticals' Total Liabilities is comparatively stable compared to the past year. Property Plant And Equipment Gross is likely to gain to about 6 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 15.9 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	40.8M	72.7M	110.4M	115.9M
Total Assets	136.8M	259.5M	170.9M	102.1M

Short Long Term Debt Total Total Assets

Marinus Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment
Total Assets		0.62	0.89	0.83	0.69	0.81	0.55	-0.77	-0.82	0.88	0.99	0.58	0.8	0.4	1.0	0.67	0.78	0.75	0.88	0.74	0.83	-0.59	1.0	0.08	0.67	0.8
Short Long Term Debt Total	0.62		0.78	0.88	-0.08	0.89	0.4	-0.02	-0.88	0.58	0.55	0.25	0.27	0.03	0.61	0.32	0.91	0.85	0.8	0.98	0.9	-0.3	0.63	0.76	0.32	0.89
Other Current Liab	0.89	0.78		0.96	0.37	0.82	0.37	-0.55	-0.81	0.81	0.88	0.5	0.77	0.27	0.89	0.42	0.81	0.73	0.8	0.88	0.88	-0.35	0.88	0.26	0.43	0.82
Total Current Liabilities	0.83	0.88	0.96		0.22	0.88	0.4	-0.39	-0.9	0.79	0.8	0.44	0.68	0.33	0.82	0.42	0.91	0.83	0.86	0.95	0.94	-0.38	0.83	0.4	0.42	0.88
Total Stockholder Equity	0.69	-0.08	0.37	0.22		0.3	0.45	-0.95	-0.3	0.55	0.74	0.52	0.68	0.44	0.69	0.62	0.23	0.29	0.48	0.07	0.28	-0.57	0.67	-0.48	0.62	0.29
Property Plant And Equipment Net	0.81	0.89	0.82	0.88	0.3		0.56	-0.34	-0.97	0.74	0.75	0.47	0.47	0.17	0.79	0.67	0.96	0.9	0.95	0.92	0.99	-0.53	0.8	0.5	0.67	1.0
Current Deferred Revenue	0.55	0.4	0.37	0.4	0.45	0.56		-0.37	-0.56	0.59	0.51	0.38	0.27	0.18	0.53	0.61	0.5	0.56	0.65	0.42	0.53	-0.78	0.54	0.28	0.62	0.56
Net Debt	-0.77	-0.02	-0.55	-0.39	-0.95	-0.34	-0.37		0.35	-0.65	-0.83	-0.49	-0.84	-0.5	-0.78	-0.55	-0.29	-0.31	-0.5	-0.19	-0.36	0.48	-0.76	0.47	-0.55	-0.33
Retained Earnings	-0.82	-0.88	-0.81	-0.9	-0.3	-0.97	-0.56	0.35		-0.73	-0.77	-0.44	-0.51	-0.35	-0.81	-0.62	-0.99	-0.96	-0.97	-0.92	-0.98	0.52	-0.82	-0.5	-0.62	-0.97
Accounts Payable	0.88	0.58	0.81	0.79	0.55	0.74	0.59	-0.65	-0.73		0.87	0.42	0.69	0.22	0.89	0.66	0.67	0.61	0.78	0.69	0.77	-0.67	0.89	0.06	0.66	0.74
Cash	0.99	0.55	0.88	0.8	0.74	0.75	0.51	-0.83	-0.77	0.87		0.54	0.85	0.43	0.99	0.63	0.73	0.71	0.84	0.69	0.78	-0.56	0.99	0.01	0.63	0.75
Non Current Assets Total	0.58	0.25	0.5	0.44	0.52	0.47	0.38	-0.49	-0.44	0.42	0.54		0.58	0.34	0.52	0.44	0.4	0.38	0.52	0.35	0.49	-0.46	0.5	-0.2	0.44	0.47
Non Currrent Assets Other	0.8	0.27	0.77	0.68	0.68	0.47	0.27	-0.84	-0.51	0.69	0.85	0.58		0.67	0.81	0.37	0.48	0.45	0.58	0.45	0.55	-0.34	0.78	-0.33	0.37	0.46
Other Assets	0.4	0.03	0.27	0.33	0.44	0.17	0.18	-0.5	-0.35	0.22	0.43	0.34	0.67		0.4	0.14	0.34	0.41	0.39	0.13	0.24	-0.23	0.38	-0.31	0.14	0.17
Cash And Short Term Investments	1.0	0.61	0.89	0.82	0.69	0.79	0.53	-0.78	-0.81	0.89	0.99	0.52	0.81	0.4		0.65	0.77	0.74	0.86	0.73	0.81	-0.57	1.0	0.08	0.65	0.79
Common Stock Total Equity	0.67	0.32	0.42	0.42	0.62	0.67	0.61	-0.55	-0.62	0.66	0.63	0.44	0.37	0.14	0.65		0.52	0.49	0.69	0.39	0.61	-0.69	0.66	-0.03	1.0	0.66
Common Stock Shares Outstanding	0.78	0.91	0.81	0.91	0.23	0.96	0.5	-0.29	-0.99	0.67	0.73	0.4	0.48	0.34	0.77	0.52		0.97	0.95	0.94	0.97	-0.45	0.78	0.55	0.52	0.96
Other Current Assets	0.75	0.85	0.73	0.83	0.29	0.9	0.56	-0.31	-0.96	0.61	0.71	0.38	0.45	0.41	0.74	0.49	0.97		0.93	0.87	0.9	-0.43	0.76	0.55	0.49	0.9
Other Stockholder Equity	0.88	0.8	0.8	0.86	0.48	0.95	0.65	-0.5	-0.97	0.78	0.84	0.52	0.58	0.39	0.86	0.69	0.95	0.93		0.85	0.95	-0.66	0.87	0.37	0.7	0.95
Total Liab	0.74	0.98	0.88	0.95	0.07	0.92	0.42	-0.19	-0.92	0.69	0.69	0.35	0.45	0.13	0.73	0.39	0.94	0.87	0.85		0.95	-0.36	0.74	0.63	0.39	0.92
Property Plant And Equipment Gross	0.83	0.9	0.88	0.94	0.28	0.99	0.53	-0.36	-0.98	0.77	0.78	0.49	0.55	0.24	0.81	0.61	0.97	0.9	0.95	0.95		-0.5	0.83	0.48	0.62	0.99
Preferred Stock Total Equity	-0.59	-0.3	-0.35	-0.38	-0.57	-0.53	-0.78	0.48	0.52	-0.67	-0.56	-0.46	-0.34	-0.23	-0.57	-0.69	-0.45	-0.43	-0.66	-0.36	-0.5		-0.57	-0.03	-0.69	-0.53
Total Current Assets	1.0	0.63	0.88	0.83	0.67	0.8	0.54	-0.76	-0.82	0.89	0.99	0.5	0.78	0.38	1.0	0.66	0.78	0.76	0.87	0.74	0.83	-0.57		0.11	0.66	0.8
Short Term Debt	0.08	0.76	0.26	0.4	-0.48	0.5	0.28	0.47	-0.5	0.06	0.01	-0.2	-0.33	-0.31	0.08	-0.03	0.55	0.55	0.37	0.63	0.48	-0.03	0.11		-0.03	0.51
Common Stock	0.67	0.32	0.43	0.42	0.62	0.67	0.62	-0.55	-0.62	0.66	0.63	0.44	0.37	0.14	0.65	1.0	0.52	0.49	0.7	0.39	0.62	-0.69	0.66	-0.03		0.67
Property Plant Equipment	0.8	0.89	0.82	0.88	0.29	1.0	0.56	-0.33	-0.97	0.74	0.75	0.47	0.46	0.17	0.79	0.66	0.96	0.9	0.95	0.92	0.99	-0.53	0.8	0.51	0.67

Click cells to compare fundamentals

Marinus Pharmaceuticals Account Relationship Matchups

Marinus Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	98.8M	150.5M	136.8M	259.5M	170.9M	102.1M
Other Current Liab	4.8M	8.0M	21.2M	46.9M	22.1M	23.2M
Total Current Liabilities	8.0M	10.7M	40.6M	54.9M	40.6M	42.7M
Total Stockholder Equity	87.8M	137.2M	53.5M	116M	16.8M	15.9M
Property Plant And Equipment Net	2.3M	1.9M	2.5M	4.2M	4.8M	5.1M
Net Debt	(90.5M)	(138.0M)	(82.1M)	(167.9M)	(10.2M)	(10.7M)
Retained Earnings	(235.6M)	(311.9M)	(410.7M)	(430.5M)	(571.9M)	(543.3M)
Accounts Payable	2.8M	2.2M	3.1M	6.3M	4.0M	2.6M
Cash	90.9M	138.5M	122.9M	240.6M	120.6M	88.1M
Non Current Assets Total	4.7M	10.3M	13.9M	19.0M	5.7M	7.8M
Non Currrent Assets Other	2.4M	6.9M	11.4M	14.7M	819.0K	778.0K
Cash And Short Term Investments	91.7M	138.5M	122.9M	240.6M	150.3M	92.1M
Common Stock Total Equity	53K	87K	37K	50K	57.5K	35.9K
Common Stock Shares Outstanding	13.6M	27.3M	36.7M	39.1M	53.7M	56.4M
Liabilities And Stockholders Equity	98.8M	150.5M	136.8M	259.5M	170.9M	102.1M
Other Current Assets	2.5M	6.3M	6.1M	5.4M	8.7M	9.2M
Other Stockholder Equity	295.1M	444.6M	459.9M	542.4M	588.7M	618.1M
Total Liab	11.1M	13.3M	83.4M	143.5M	154.1M	161.9M
Property Plant And Equipment Gross	2.3M	1.9M	3.9M	5.7M	5.7M	6.0M
Total Current Assets	94.1M	140.2M	122.9M	240.6M	165.2M	94.3M
Accumulated Other Comprehensive Income	(96K)	(2K)	0.0	(20K)	(23K)	(24.2K)
Common Stock	53K	87K	37K	50K	55K	37.9K
Property Plant Equipment	2.3M	1.9M	2.5M	4.2M	4.9M	5.1M
Net Tangible Assets	87.8M	132.7M	53.5M	112.0M	128.8M	76.0M
Retained Earnings Total Equity	(235.6M)	(311.9M)	(410.7M)	(430.5M)	(387.5M)	(368.1M)
Short Term Investments	19.9M	5.0M	739K	1.5M	29.7M	31.2M
Non Current Liabilities Total	3.0M	2.5M	42.8M	88.6M	113.5M	119.2M
Capital Surpluse	295.1M	444.6M	459.9M	542.4M	623.8M	317.7M
Net Invested Capital	59.6M	132.7M	40.8M	71.0M	89.7M	81.7M

Pair Trading with Marinus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marinus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marinus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Marinus Stock

0.68	VRAX	Virax Biolabs Group Fiscal Year End 12th of June 2024	Pair Corr
0.8	JNJ	Johnson Johnson Aggressive Push	Pair Corr

Moving against Marinus Stock

0.87	RZLT	Rezolute Fiscal Year End 12th of September 2024	Pair Corr
0.71	SNDL	SNDL Inc	Pair Corr
0.49	NTRB	Nutriband Financial Report 14th of June 2024	Pair Corr

The ability to find closely correlated positions to Marinus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marinus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marinus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marinus Pharmaceuticals to buy it.

The correlation of Marinus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marinus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marinus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Marinus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Marinus Pharmaceuticals is a strong investment it is important to analyze Marinus Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Marinus Pharmaceuticals' future performance. For an informed investment choice regarding Marinus Stock, refer to the following important reports:

How To Invest In Marinus

Details

Is Marinus Stock a good investment?

Details

What is Marinus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Marinus Stock analysis

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Money Managers Screen money managers from public funds and ETFs managed around the world

Is Marinus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marinus Pharmaceuticals. If investors know Marinus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marinus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.64)

Revenue Per Share

0.514

Quarterly Revenue Growth

(0.26)

Return On Assets

(0.46)

Return On Equity

(4.23)

The market value of Marinus Pharmaceuticals is measured differently than its book value, which is the value of Marinus that is recorded on the company's balance sheet. Investors also form their own opinion of Marinus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Marinus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marinus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Marinus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Marinus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marinus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marinus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Marinus Historical Balance Sheet

Marinus Pharmaceuticals Inventory

2.53 Million

About Marinus Balance Sheet Analysis

Marinus Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Marinus Pharmaceuticals balance sheet Correlations

Marinus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Marinus Pharmaceuticals balance sheet Accounts

Pair Trading with Marinus Pharmaceuticals

Moving together with Marinus Stock

Moving against Marinus Stock

Complementary Tools for Marinus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash	+ 0.99	Total Assets

Common Stock Shares Outstanding	- 0.99	Retained Earnings
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Property Plant Equipment	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net
Other Current Assets	- 0.96	Retained Earnings